ArticleBriefings in bioinformatics2025
Advancing ADMET prediction through multiscale fragment-aware pretraining with MSformer-ADMET.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI.Clinical pharmacology and therapeutics · 2026Review
- A Systematic Survey and Benchmark of Deep Learning for Molecular Property Prediction in the Foundation Model Era.Journal of chemical theory and computation · 2026Review
- A hierarchical interaction message net for accurate molecular property prediction.Communications chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties are critical determinants of the pharmacokinetic and safety profiles of drug candidates. Accurate and early-stage prediction of ADMET characteristics is essential for reducing late-stage attrition rates, lowering development costs, and accelerating the drug discovery process. Recent advances in deep learning have shown great promise in molecular property prediction, especially with the emergence of Transformer-based architectures that can effectively model long-range dependencies in molecular representations. However, most existing methods rely heavily on atom-level encodings (e.g. smiles or molecular graphs), which often lack structural interpretability and generalization across heterogeneous tasks. Previously, we developed a de novo and flexible molecular representation framework named MSformer (available at https://github.com/ZJUFanLab/MSformer), which demonstrated success in bioactivity prediction. We have now adapted and specialized this architecture for ADMET property prediction. This adapted implementation, designated as MSformer-ADMET, extends the framework's capabilities to pharmacokinetic and toxicity endpoints while maintaining its flexible, fragmentation-based approach to molecular representation learning. MSformer-ADMET is fine-tuned on 22 tasks collected from the Therapeutics Data Commons (TDC), covering both classification and regression settings. Results demonstrate that MSformer-ADMET achieves superior performance across a wide range of ADMET endpoints, consistently outperforming conventional smiles-based and graph-based models. Notably, we further conducted interpretability analyses by leveraging the model's attention distributions and fragment-to-atom mappings, allowing the identification of key structural fragments that are highly associated with molecular properties. This post hoc interpretability provides more transparent insights into the structure-property relationship. Collectively, results demonstrate that MSformer-ADMET is a highly effective and broadly applicable model for ADMET prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.